TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Faruqi & Faruqi, Llp
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute's stock plummeted on December 11, 2025, following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug, a lead drug candidate for congenital hyperinsulinism. The study failed to meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events versus placebo. Securities law firm Faruqi & Faruqi is investigating potential claims against the company on behalf of affected investors.

Insights
RZLT   negative

The company's lead drug candidate failed to meet primary and secondary endpoints in Phase 3 trials, resulting in sharp stock decline and triggering securities litigation investigation. This represents a significant setback for the company's pipeline and investor confidence.